SCHEMBL2674700

SCHEMBL2674700

O=C(c1cccc(Br)c1-c1ccccc1)c1cccc(Br)c1-c1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FABP4 P15090 3/20 0.58
▸ PRNP P04156 1/20 0.51
▸ MEN1 O00255 3/20 0.45
▸ KMT2A Q03164 3/20 0.45
▸ HNF4A P41235 1/20 0.44
▸ ALDH1A1 P00352 3/20 0.41
▸ HTT P42858 2/20 0.41
▸ AKR1C3 P42330 2/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ AKR1C4 P17516 1/20 0.41
▸ AKR1C2 P52895 1/20 0.41
▸ AKR1C1 Q04828 1/20 0.41
▸ GSTA1 P08263 1/20 0.41
▸ MAPT P10636 2/20 0.40
▸ TDP1 Q9NUW8 2/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ PIM1 P11309 1/20 0.40
▸ GFER P55789 1/20 0.40
▸ CDC25B P30305 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8895763 0.88 FABP4 (0.68) FABP4PRNPKMT2AHNF4AALDH1A1
SCHEMBL27950189 0.85 FABP4 (0.55) FABP4PRNPHNF4AALDH1A1MAPT
SCHEMBL28289664 0.80 FABP4 (0.55) FABP4MEN1KMT2AALDH1A1HTT
SCHEMBL27933541 0.80 FABP4 (0.51) FABP4PRNPMEN1KMT2AHNF4A
SCHEMBL8973903 0.78 ALDH1A1 (0.55) FABP4MEN1KMT2AALDH1A1HTT
SCHEMBL8778491 0.78 HNF4A (0.60) FABP4MEN1KMT2AHNF4AALDH1A1
SCHEMBL28789332 0.77 FABP4 (0.47) FABP4PRNPMEN1KMT2AHNF4A
SCHEMBL11625438 0.77 WDR5 (0.51) FABP4PRNPMEN1KMT2AALDH1A1
SCHEMBL6748515 0.76 MAPT (0.52) FABP4MEN1KMT2AHNF4AALDH1A1
SCHEMBL28409589 0.76 FABP4 (0.58) FABP4MEN1KMT2AHNF4AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173696-B2 Inhibitors of cysteine proteases and methods of use thereof BAYLOR UNIVERSITY (US) 2012-05-08 — — US disclosed
US-20090076076-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF BAYLOR UNIVERSITY (US) 2009-03-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076076-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF CTSB, CTSS, CTSZ FABP4 3879/4885PRNP 1693/4885MEN1 2515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback